34 related articles for article (PubMed ID: 21566522)
1. Quisinostat is a brain-penetrant radiosensitizer in glioblastoma.
Lo Cascio C; Margaryan T; Luna-Melendez E; McNamara JB; White CI; Knight W; Ganta S; Opachich Z; Cantoni C; Yoo W; Sanai N; Tovmasyan A; Mehta S
JCI Insight; 2023 Nov; 8(22):. PubMed ID: 37991020
[TBL] [Abstract][Full Text] [Related]
2. GSE1 links the HDAC1/CoREST co-repressor complex to DNA damage.
Vcelkova T; Reiter W; Zylka M; Hollenstein DM; Schuckert S; Hartl M; Seiser C
Nucleic Acids Res; 2023 Nov; 51(21):11748-11769. PubMed ID: 37878419
[TBL] [Abstract][Full Text] [Related]
3. Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy.
Everix L; Seane EN; Ebenhan T; Goethals I; Bolcaen J
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259375
[TBL] [Abstract][Full Text] [Related]
4. HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny.
Nakagawa-Saito Y; Saitoh S; Mitobe Y; Sugai A; Togashi K; Suzuki S; Kitanaka C; Okada M
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897656
[TBL] [Abstract][Full Text] [Related]
5. Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression.
Hanisch D; Krumm A; Diehl T; Stork CM; Dejung M; Butter F; Kim E; Brenner W; Fritz G; Hofmann TG; Roos WP
Cell Death Dis; 2022 Apr; 13(4):293. PubMed ID: 35365623
[TBL] [Abstract][Full Text] [Related]
6. Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.
Vengoji R; Atri P; Macha MA; Seshacharyulu P; Perumal N; Mallya K; Liu Y; Smith LM; Rachagani S; Mahapatra S; Ponnusamy MP; Jain M; Batra SK; Shonka N
J Exp Clin Cancer Res; 2021 Oct; 40(1):335. PubMed ID: 34696786
[TBL] [Abstract][Full Text] [Related]
7. CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models.
Antonelli R; Jiménez C; Riley M; Servidei T; Riccardi R; Soriano A; Roma J; Martínez-Saez E; Martini M; Ruggiero A; Moreno L; Sánchez de Toledo J; Gallego S; Bové J; Hooker JM; Segura MF
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708733
[TBL] [Abstract][Full Text] [Related]
8. The application of histone deacetylases inhibitors in glioblastoma.
Chen R; Zhang M; Zhou Y; Guo W; Yi M; Zhang Z; Ding Y; Wang Y
J Exp Clin Cancer Res; 2020 Jul; 39(1):138. PubMed ID: 32682428
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
[TBL] [Abstract][Full Text] [Related]
10. [MACF1 knockdown in glioblastoma multiforme cells increases temozolomide-induced cytotoxicity].
Xie SD; Chen ZY; Wang H; He MY; Lu YT; Lei BX; Li HZ; Liu YW; Qi ST
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Sep; 37(9):1183-1189. PubMed ID: 28951359
[TBL] [Abstract][Full Text] [Related]
11. Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma.
Kong LR; Tan TZ; Ong WR; Bi C; Huynh H; Lee SC; Chng WJ; Eichhorn PJA; Goh BC
Mol Oncol; 2017 Aug; 11(8):965-980. PubMed ID: 28397399
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics in Brain Tumors: HDACs Take Center Stage.
Eyüpoglu IY; Savaskan NE
Curr Neuropharmacol; 2016; 14(1):48-54. PubMed ID: 26521944
[TBL] [Abstract][Full Text] [Related]
13. Targeting of histone deacetylases in brain tumors.
Ecker J; Witt O; Milde T
CNS Oncol; 2013 Jul; 2(4):359-76. PubMed ID: 25054580
[TBL] [Abstract][Full Text] [Related]
14. Systems biology of cisplatin resistance: past, present and future.
Galluzzi L; Vitale I; Michels J; Brenner C; Szabadkai G; Harel-Bellan A; Castedo M; Kroemer G
Cell Death Dis; 2014 May; 5(5):e1257. PubMed ID: 24874729
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Bezecny P
Med Oncol; 2014 Jun; 31(6):985. PubMed ID: 24838514
[TBL] [Abstract][Full Text] [Related]
16. Histone acetylation: molecular mnemonics on the chromatin.
Gräff J; Tsai LH
Nat Rev Neurosci; 2013 Feb; 14(2):97-111. PubMed ID: 23324667
[TBL] [Abstract][Full Text] [Related]
17. Deregulated chromatin remodeling in the pathobiology of brain tumors.
Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
[TBL] [Abstract][Full Text] [Related]
18. Novel therapies in glioblastoma.
Perry J; Okamoto M; Guiou M; Shirai K; Errett A; Chakravarti A
Neurol Res Int; 2012; 2012():428565. PubMed ID: 22530121
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275.
Bangert A; Häcker S; Cristofanon S; Debatin KM; Fulda S
Anticancer Drugs; 2011 Jul; 22(6):494-9. PubMed ID: 21566522
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
